I have been working with Chinese Hamster Ovary (CHO) cells for 13 or so years, and I have learned a lot of useful lessons about their stable transfection, maintenance of expression, and other things.
What problems are most significant, from your experience, when using CHO cells for producing proteins for biotherapeutics? Are you satisfied with using antibiotic resistance? Do you use Dihydrofolate Reductase (DHFR) negative cells for selection? Are you satisfied with your current method for cryopreservation, or are there burdensome limitations?
Hi Adam, my answer will probably not help you, but I have worked for Big Pharma.
The bottom line is: if a drug works and it is approved by the FDA, don't change anything for its production. And I mean DON'T CHANGE ANYTHING!!
If you want to change the production procedure for a drug, you have to file and request an amendment to the already approved FDA procedure and wait to get an OK from the FDA for the change after you produce a ton of data that shows an improvement in the production of a drug. And that can take years and a lot of $$$.
So Big Pharma says: what the Eff. We have a product on the market and it is making money for us right now. We have a production line. Why should we mess with it.
This procedure makes Kafka proud.
- Badges
- Science topic
- Similar topics
- Biological Science
- Molecular Biology
- Molecular Methods
- Cloning